Design of HIV VLPs with Enhanced Immunogenicity

具有增强免疫原性的 HIV VLP 的设计

基本信息

  • 批准号:
    8075656
  • 负责人:
  • 金额:
    $ 49.22万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2010
  • 资助国家:
    美国
  • 起止时间:
    2010-06-01 至 2014-05-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A prophylactic HIV-1 vaccine is urgently needed, and an antigen that elicits strong broadly reactive neutralizing antibody (nAb) responses against the viral envelope glycoprotein would be an important component. However, the challenges in vaccine development include the extraordinary genetic diversity and immune evasion capacity of HIV-1 and the limited availability of epitopes for broadly nAbs. Immunogens that mimic an important process in natural infection and initiate appropriate innate immune responses are expected to be advantageous. Virus-like particles (VLPs) represent an attractive approach to present Env in a form similar to its exposure on virions. We recently reported that modified Env proteins can be designed to be incorporated into VLPs at very high levels (Wang, 2007). We hypothesize that VLPs containing such modified Env will elicit enhanced nAb responses, and are proposing additional new approaches to generate VLPs with greater immunogenicity. One approach will focus on enhancing the incorporation of stable Env trimers into VLPs. Alternatively, VLP immunogenicity will be enhanced by incorporation of molecular adjuvants, including a membrane -anchored form of flagellin, the natural ligand of the toll-like receptor 5 (TLR5), or a membrane- anchored form of GM-CSF. We expect that the resulting VLPs will elicit improved neutralizing antibody responses, as well as cell-mediated cellular immunity. We hypothesize that these novel VLPs will elicit higher titers of broadly reactive nAbs and enhanced mucosal immune responses when administered by mucosal inoculation, and we will test this hypothesis in a guinea pig model. Because DNA vaccines are effective in priming antibody responses as well as eliciting cellular responses (Singh et al., 2005), as a comparison we will also generate DNA constructs expressing clade B and C Env and Gag for use in priming by DNA vaccines, including a cross-clade DNA prime-VLP boost regimen to focus cross-clade immunity. Our goal is to develop an HIV vaccine that is effective at reducing the incidence of infection at mucosal surfaces. The combination of Env antigen presentation in its native state combined with a membrane-anchored adjuvant and mucosal delivery provides a promising approach to stimulate strong nAb response against HIV, designed to block the initial step in the infection process. Because of the relatively low efficiency of HIV transmission at mucosal surfaces, even a modest enhancement of protective mucosal responses could have a significant effect on reducing disease incidence. Among the possible outcomes which may result in such enhanced protection are: increasing the magnitude and/or duration of the response, increasing the breadth of cross-reactivity of the responses, and enhancing the levels of responses at local mucosal sites. Despite tremendous efforts, an effective vaccine for AIDS prevention remains elusive and novel approaches are needed. Our research is focused on developing novel particulate antigens that will elicit broadly reactive neutralizing antibody responses as well as cell-mediated immunity. We will also focus on enhancing immune responses at mucosal surfaces, where most HIV infections are transmitted.
描述(由申请人提供): 迫切需要一种预防性的HIV-1疫苗,而能够引起针对病毒包膜糖蛋白的广谱中和抗体(NAB)反应的抗原将是一个重要的组成部分。然而,疫苗开发中的挑战包括HIV-1非凡的遗传多样性和免疫逃避能力,以及可用于广泛NAB的表位有限。模拟自然感染中的一个重要过程并启动适当的先天免疫反应的免疫原被认为是有利的。病毒样颗粒(VLP)代表了一种诱人的方法来呈现Env,其形式类似于其在病毒粒子上的暴露。我们最近报道了修饰的Env蛋白可以被设计成以非常高的水平整合到VLP中(Wang,2007)。我们假设,含有这种修饰的Env的VLP将引起增强的NAB反应,并正在提出其他新的方法来产生具有更强免疫原性的VLP。一种方法将侧重于加强将稳定的环境三聚体纳入VLP。或者,VLP的免疫原性将通过掺入分子佐剂来增强,包括膜锚定形式的鞭毛蛋白、Toll样受体5(TLR5)的天然配体或膜锚定形式的GM-CSF。我们预计,由此产生的VLP将引起更好的中和抗体反应,以及细胞介导的细胞免疫。我们假设,这些新的VLP将引起更高的广泛反应的NAB滴度和增强的粘膜免疫反应时,通过粘膜接种,我们将在豚鼠模型中测试这一假设。由于DNA疫苗在引发抗体反应和引发细胞反应方面是有效的(Singh等人,2005年),作为比较,我们还将产生表达分支B和C环境和GAG的DNA构建体,用于DNA疫苗的启动,包括集中跨分支免疫的跨分支DNA Prime-VLP Boost方案。我们的目标是开发一种有效减少粘膜表面感染的艾滋病毒疫苗。天然状态的Env抗原递呈与膜锚定佐剂和粘膜递送相结合,为激发针对HIV的强大NAB反应提供了一种有前景的方法,旨在阻断感染过程的初始步骤。由于艾滋病毒在粘膜表面的传播效率相对较低,即使适度增强粘膜保护性反应,也可能对降低发病率产生重大影响。可能导致这种增强保护的结果包括:增加反应的幅度和/或持续时间,增加反应的交叉反应的广度,以及提高局部粘膜部位的反应水平。尽管作出了巨大努力,但预防艾滋病的有效疫苗仍然难以找到,需要新的方法。我们的研究集中在开发新的颗粒抗原,它将引起广泛的反应性中和抗体反应以及细胞介导的免疫。我们还将重点加强粘膜表面的免疫反应,大多数艾滋病毒感染都是在粘膜表面传播的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD W COMPANS其他文献

RICHARD W COMPANS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD W COMPANS', 18)}}的其他基金

Skin Vaccination Against Influenza in the Young And Aged
年轻人和老年人的流感皮肤疫苗接种
  • 批准号:
    9210049
  • 财政年份:
    2015
  • 资助金额:
    $ 49.22万
  • 项目类别:
Skin Vaccination Against Influenza in the Young And Aged
年轻人和老年人的流感皮肤疫苗接种
  • 批准号:
    8886505
  • 财政年份:
    2015
  • 资助金额:
    $ 49.22万
  • 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
  • 批准号:
    8257884
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
  • 批准号:
    8650780
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
  • 批准号:
    8463750
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
INFLUENZA PATHOGENESIS & IMMUNOLOGY RESEARCH CENTER (IPIRC)
流感发病机制
  • 批准号:
    8357468
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
  • 批准号:
    8076663
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
A dual vaccine strategy against filovirus infection
针对丝状病毒感染的双重疫苗策略
  • 批准号:
    8837557
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
VLP VACCINES FOR HIV PREVENTION
用于预防 HIV 的 VLP 疫苗
  • 批准号:
    8357486
  • 财政年份:
    2011
  • 资助金额:
    $ 49.22万
  • 项目类别:
Design of HIV VLPs with Enhanced Immunogenicity
具有增强免疫原性的 HIV VLP 的设计
  • 批准号:
    8278665
  • 财政年份:
    2010
  • 资助金额:
    $ 49.22万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 49.22万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了